Evolus (EOLS) Competitors $12.60 -0.44 (-3.37%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EOLS vs. ADMS, MLTX, PTCT, AGIO, HCM, XENE, EWTX, VRNA, DYN, and BHCShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Adamas Pharmaceuticals (ADMS), MoonLake Immunotherapeutics (MLTX), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Verona Pharma (VRNA), Dyne Therapeutics (DYN), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector. Evolus vs. Adamas Pharmaceuticals MoonLake Immunotherapeutics PTC Therapeutics Agios Pharmaceuticals HUTCHMED Xenon Pharmaceuticals Edgewise Therapeutics Verona Pharma Dyne Therapeutics Bausch Health Companies Adamas Pharmaceuticals (NASDAQ:ADMS) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Is ADMS or EOLS more profitable? Evolus has a net margin of -22.33% compared to Adamas Pharmaceuticals' net margin of -71.11%. Adamas Pharmaceuticals' return on equity of 0.00% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Adamas Pharmaceuticals-71.11% N/A -42.96% Evolus -22.33%-847.60%-22.15% Does the media refer more to ADMS or EOLS? In the previous week, Evolus had 3 more articles in the media than Adamas Pharmaceuticals. MarketBeat recorded 3 mentions for Evolus and 0 mentions for Adamas Pharmaceuticals. Evolus' average media sentiment score of 1.27 beat Adamas Pharmaceuticals' score of 0.00 indicating that Evolus is being referred to more favorably in the news media. Company Overall Sentiment Adamas Pharmaceuticals Neutral Evolus Positive Do insiders & institutionals have more ownership in ADMS or EOLS? 70.0% of Adamas Pharmaceuticals shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 18.9% of Adamas Pharmaceuticals shares are held by insiders. Comparatively, 6.1% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend ADMS or EOLS? Evolus has a consensus target price of $23.00, indicating a potential upside of 82.54%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Adamas Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adamas Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ADMS or EOLS? Adamas Pharmaceuticals received 50 more outperform votes than Evolus when rated by MarketBeat users. However, 72.58% of users gave Evolus an outperform vote while only 57.26% of users gave Adamas Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdamas PharmaceuticalsOutperform Votes40257.26% Underperform Votes30042.74% EvolusOutperform Votes35272.58% Underperform Votes13327.42% Which has more volatility & risk, ADMS or EOLS? Adamas Pharmaceuticals has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Which has better earnings & valuation, ADMS or EOLS? Adamas Pharmaceuticals has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Adamas Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdamas Pharmaceuticals$74.46M5.05-$57.40M-$1.70-4.84Evolus$248.33M3.21-$61.69M-$0.91-13.85 SummaryEvolus beats Adamas Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$797.85M$6.65B$5.17B$8.83BDividend YieldN/A8.11%5.05%4.09%P/E Ratio-13.8510.57116.1217.50Price / Sales3.21369.511,244.07159.46Price / CashN/A52.5939.8036.27Price / Book140.0010.357.056.49Net Income-$61.69M$153.21M$118.73M$225.45M7 Day Performance4.05%4.45%2.15%3.61%1 Month Performance-21.45%-7.83%-3.06%3.48%1 Year Performance34.04%33.22%33.51%29.13% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus4.0382 of 5 stars$12.60-3.4%$23.00+82.5%+34.0%$797.85M$248.33M-13.85170Positive NewsADMSAdamas PharmaceuticalsN/A$8.22flatN/AN/A$376.37M$74.46M-4.84138MLTXMoonLake Immunotherapeutics3.4771 of 5 stars$51.86+4.1%$79.00+52.3%+19.9%$3.31BN/A-38.432News CoveragePTCTPTC Therapeutics2.5891 of 5 stars$42.89+2.2%$42.00-2.1%+100.0%$3.24B$900.66M-7.221,410Analyst DowngradeAGIOAgios Pharmaceuticals3.3042 of 5 stars$55.54+1.7%$52.33-5.8%+153.6%$3.17B$26.82M4.89390HCMHUTCHMED1.1761 of 5 stars$17.70-1.4%$20.55+16.1%-4.8%$3.13B$420.26M0.001,988News CoverageXENEXenon Pharmaceuticals3.5584 of 5 stars$39.97+1.6%$57.45+43.7%+43.2%$3.05B$9.43M-13.95251Insider TradeEWTXEdgewise Therapeutics2.7014 of 5 stars$32.10+0.4%$38.40+19.6%+404.7%$3.04BN/A-21.4060Analyst ForecastNews CoverageGap UpVRNAVerona Pharma2.6481 of 5 stars$38.01-2.2%$43.83+15.3%+176.2%$3.04B$460,000.00-19.7930Positive NewsDYNDyne Therapeutics3.4141 of 5 stars$29.79-0.7%$51.40+72.5%+182.2%$3.03BN/A-8.37100BHCBausch Health Companies3.5643 of 5 stars$8.17-0.2%$7.75-5.1%+15.9%$3.00B$8.76B-17.0220,270Analyst RevisionPositive News Related Companies and Tools Related Companies Adamas Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors PTC Therapeutics Competitors Agios Pharmaceuticals Competitors HUTCHMED Competitors Xenon Pharmaceuticals Competitors Edgewise Therapeutics Competitors Verona Pharma Competitors Dyne Therapeutics Competitors Bausch Health Companies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EOLS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts